# ä¹³è…ºç™Œä¸´åºŠè¯•éªŒæŠ¥å‘Š

**ç”Ÿæˆæ—¥æœŸ**: 2025-06-07
**æŸ¥è¯¢æ¡ä»¶**: ä¹³è…ºç™Œç›¸å…³çš„æ´»è·ƒä¸´åºŠè¯•éªŒ
**æŸ¥è¯¢èŒƒå›´**: æœ€è¿‘30å¤©å†…æ–°å¢æˆ–æ›´æ–°çš„è¯•éªŒ
**è¯•éªŒæ€»æ•°**: 10
**æ™ºèƒ½ç¿»è¯‘**: âœ… å·²å¯ç”¨

> ğŸ“ **è¯´æ˜**: æœ¬æŠ¥å‘Šæä¾›ä¸­è‹±æ–‡å¯¹ç…§ä¿¡æ¯ï¼Œå…³é”®åŒ»å­¦æœ¯è¯­ä¿æŒåŸæ–‡ä»¥ç¡®ä¿å‡†ç¡®æ€§ã€‚

## è¯•éªŒåˆ—è¡¨

### æ­£åœ¨æ‹›å‹Ÿçš„è¯•éªŒ

## ä¸€é¡¹ç ”ç©¶Sacituzumab Tirumotecanï¼ˆSac-TMTï¼ŒMK-2870ï¼‰å•è¯æ²»ç–—åŠä¸Pembrolizumabï¼ˆMK-3475ï¼‰è”åˆæ²»ç–—ä¸‰é˜´æ€§ä¹³è…ºç™Œæ‚£è€…çš„ç ”ç©¶ï¼ˆMK-2870-011/TroFuse-011ï¼‰ã€‚

<details>
<summary>ğŸ” æŸ¥çœ‹è‹±æ–‡åŸæ–‡</summary>

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

</details>

**è¯•éªŒç¼–å·**: NCT06841354  
**æ­£å¼æ ‡é¢˜**: ä¸€é¡¹ç¬¬3æœŸã€éšæœºã€å¼€æ”¾æ ‡ç­¾ç ”ç©¶ï¼Œæ¯”è¾ƒSacituzumab Tirumotecanï¼ˆSac-TMTï¼ŒMK-2870ï¼‰å•è¯æ²»ç–—ä¸è”åˆPembrolizumabï¼ˆMK-3475ï¼‰æ²»ç–—ï¼Œä¸åŒ»ç”Ÿé€‰æ‹©çš„æ²»ç–—æ–¹æ¡ˆï¼Œåœ¨æœªæ›¾æ²»ç–—çš„å±€éƒ¨å¤å‘ä¸å¯åˆ‡é™¤æˆ–è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œæ‚£è€…ä¸­çš„ç–—æ•ˆä¸å®‰å…¨æ€§ï¼Œè¿™äº›æ‚£è€…çš„PD-L1è¡¨è¾¾CPSå°äº10ï¼ˆTroFuse-011ï¼‰ã€‚

<details>
<summary>ğŸ” æŸ¥çœ‹è‹±æ–‡åŸæ–‡</summary>

A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)

</details>  
**ç–¾ç—…æ¡ä»¶**: ä¸‰é˜´æ€§ä¹³è…ºç™Œç—…å˜ (Triple Negative Breast Neoplasms)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE3  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: å¡æ›¿ç å•æŠ— tirumotecanï¼Œå¸•åšåˆ©ç å•æŠ—ï¼ŒæŠ¢æ•‘ç”¨è¯ï¼Œç´«æ‰é†‡ï¼Œç™½è›‹ç™½ç»“åˆå‹ç´«æ‰é†‡ï¼Œå‰è¥¿ä»–æ»¨ï¼Œå¡é“‚ã€‚ (Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin)  
**å¹²é¢„ç±»å‹**: ç”Ÿç‰©åˆ¶å“ï¼Œç”Ÿç‰©åˆ¶å“ï¼Œè¯ç‰©ï¼Œè¯ç‰©ï¼Œè¯ç‰©ï¼Œè¯ç‰©ï¼Œè¯ç‰©ã€‚ (BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG)  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: Merck Sharp & Dohme LLC  
**è¯•éªŒåœ°ç‚¹**: Comprehensive Cancer Centers of Nevada ( Site 0015), Las Vegas, United States; Renown Regional Medical Center ( Site 0005), Reno, United States; New Mexico Oncology Hematology Consultants Ltd. ( Site 0019), Albuquerque, United States  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 1000  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2025-02-18  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: N/A  
**ç”µè¯**: N/A  
**é‚®ç®±**: N/A  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06841354)

---

## ä¸€é¡¹ç ”ç©¶BL-M07D1ä¸ç ”ç©¶è€…é€‰æ‹©çš„åŒ–ç–—æ–¹æ¡ˆåœ¨HER2ä½è¡¨è¾¾å‹å¤å‘/è½¬ç§»æ€§ä¹³è…ºç™Œæ‚£è€…ä¸­çš„æ¯”è¾ƒã€‚ (A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer)

**è¯•éªŒç¼–å·**: NCT06957886  
**æ­£å¼æ ‡é¢˜**: ä¸€é¡¹éšæœºã€å¯¹ç…§çš„IIIæœŸç ”ç©¶ï¼Œæ¯”è¾ƒBL-M07D1ä¸ç ”ç©¶è€…é€‰æ‹©çš„åŒ–ç–—æ–¹æ¡ˆåœ¨HER2ä½è¡¨è¾¾å‹å¤å‘/è½¬ç§»æ€§ä¹³è…ºç™Œæ‚£è€…ä¸­çš„åº”ç”¨ã€‚ (A Randomized, Controlled Phase III Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer)  
**ç–¾ç—…æ¡ä»¶**: HER2ä½è¡¨è¾¾ä¹³è…ºç™Œ (HER2-low Breast Cancer)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE3  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: BL-M07D1ã€å¡åŸ¹ä»–æ»¨ã€è‰¾ç‘å¸ƒæ—ã€å‰è¥¿ä»–æ»¨ã€ç´«æ‰é†‡æˆ–ç™½è›‹ç™½ç´«æ‰é†‡ (BL-M07D1, Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel)  
**å¹²é¢„ç±»å‹**: DRUG, DRUG  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: Sichuan Baili Pharmaceutical Co., Ltd.  
**è¯•éªŒåœ°ç‚¹**: Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China; Hunan Cancer Hospital, Changsha, China  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 564  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2025-04-27  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: N/A  
**ç”µè¯**: N/A  
**é‚®ç®±**: N/A  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06957886)

---

## æ–°è¾…åŠ©åŒ–ç–—è”åˆToripalimabæ²»ç–—HR+/HER2-ä¹³è…ºç™Œï¼šä¸€é¡¹éšæœºã€å¼€æ”¾æ ‡ç­¾ã€å¹³è¡Œå¯¹ç…§çš„å¤šä¸­å¿ƒIIIæœŸç ”ç©¶ï¼ˆNEOTORCH-BREAST04ï¼‰ (Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04))

**è¯•éªŒç¼–å·**: NCT06977893  
**æ­£å¼æ ‡é¢˜**: æ–°è¾…åŠ©åŒ–ç–—è”åˆToripalimabæ²»ç–—HR+/HER2-ä¹³è…ºç™Œï¼šä¸€é¡¹éšæœºã€å¼€æ”¾æ ‡ç­¾ã€å¹³è¡Œå¯¹ç…§çš„å¤šä¸­å¿ƒIIIæœŸç ”ç©¶ï¼ˆNEOTORCH-BREAST04ï¼‰ (Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04))  
**ç–¾ç—…æ¡ä»¶**: è‹±æ–‡å†…å®¹ï¼š

HR+/HER2- Breast Cancer

ä¸­æ–‡ç¿»è¯‘ï¼š

æ¿€ç´ å—ä½“é˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ (HR+/HER2- Breast Cancer)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE3  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: æ–°è¾…åŠ©åŒ–ç–—è”åˆç‰¹ç‘æ™®åˆ©å•æŠ—ï¼Œæ–°è¾…åŠ©åŒ–ç–— (Neoadjuvant Chemotherapy in Combination with Toripalimab, Neoadjuvant Chemotherapy)  
**å¹²é¢„ç±»å‹**: DRUG, DRUG  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: First Affiliated Hospital of Zhejiang University  
**è¯•éªŒåœ°ç‚¹**: Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China; The First Affiliated Hospital of Zhejiang University, Hangzhou, China; Zhejiang Cancer Hospital, Hangzhou, China  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 194  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2025-05-12  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: N/A  
**ç”µè¯**: N/A  
**é‚®ç®±**: N/A  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06977893)

---

## ä¸€é¡¹IIIBæœŸç ”ç©¶ï¼Œè¯„ä¼°å¡çš®ç“¦å¡ç‰¹ibä¸æ°Ÿç»´å¸ç¾¤è”åˆä½¿ç”¨åœ¨æ›¾æ¥å—å†…åˆ†æ³Œæ²»ç–—ï¼ˆETï¼‰åŠCDK4/6æŠ‘åˆ¶å‰‚åå¤å‘/è¿›å±•çš„æ™šæœŸä¹³è…ºç™Œæ‚£è€…ä¸­çš„æ•ˆæœï¼Œè¯¥ç ”ç©¶åæ˜ äº†è¥¿ç­ç‰™å®é™…ä¸´åºŠå®è·µæƒ…å†µã€‚ (A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain)

**è¯•éªŒç¼–å·**: NCT06764186  
**æ­£å¼æ ‡é¢˜**: ä¸€é¡¹IIIBæœŸç ”ç©¶ï¼Œè¯„ä¼°å¡çš®ç“¦æ–¯æ›¿å¸ƒä¸æ°Ÿç»´å¸ç¾¤è”åˆä½¿ç”¨åœ¨è¥¿ç­ç‰™ä¸´åºŠå®è·µä¸­ï¼Œé’ˆå¯¹é‚£äº›å¯¹å†…åˆ†æ³Œæ²»ç–—ï¼ˆETï¼‰å’ŒCDK4/6æŠ‘åˆ¶å‰‚æ²»ç–—å¤å‘/è¿›å±•çš„HR+ / HER2-æ™šæœŸä¹³è…ºç™Œæ‚£è€…ä¸­çš„åº”ç”¨æƒ…å†µã€‚ (A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With HR+ / HER2- Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain)  
**ç–¾ç—…æ¡ä»¶**: å±€éƒ¨æ™šæœŸæˆ–è½¬ç§»æ€§ä¹³è…ºç™Œ (Locally Advanced or Metastatic Breast Cancer)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE3  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: æ°Ÿç»´å¸ç¾¤ï¼Œå¡çš®ç“¦å¡æ›¿å¸ƒ (Fulvestrant, Capivasertib)  
**å¹²é¢„ç±»å‹**: DRUG, DRUG  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: AstraZeneca  
**è¯•éªŒåœ°ç‚¹**: Research Site, Alicante, Spain; Research Site, Barcelona, Spain; Research Site, Barcelona, Spain  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 100  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2024-11-28  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: N/A  
**ç”µè¯**: N/A  
**é‚®ç®±**: N/A  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06764186)

---

## å±€éƒ¨ä½¿ç”¨å€ä»–ç±³æ¾ä¸æ¶¦è‚¤å‰‚åœ¨ä¿¯å§ä½æ²»ç–—çš„å¤§èƒ¸æ‚£è€…ä¸­é¢„é˜²æ”¾å°„æ€§çš®ç‚çš„æ¯”è¾ƒç ”ç©¶ã€‚ (Topical Betamethasone Versus Moisturizer in Preventing Radiation Dermatitis in Large-Breasted Patients Treated in the Prone Position)

**è¯•éªŒç¼–å·**: NCT06915857  
**æ­£å¼æ ‡é¢˜**: å¤§å‹ä¹³æˆ¿æ‚£è€…åœ¨ä¿¯å§ä½æ²»ç–—ä¸­ï¼Œæ¯”è¾ƒå±€éƒ¨ä½¿ç”¨å€ä»–ç±³æ¾ä¸æ¶¦è‚¤å‰‚é¢„é˜²æ”¾å°„æ€§çš®ç‚ï¼šä¸€é¡¹éšæœºç¬¬ä¸‰æœŸä¸´åºŠè¯•éªŒã€‚ (A Topical Betamethasone Versus Moisturizer in Preventing Radiation Dermatitis in Large-Breasted Patients Treated in the Prone Position: A Randomized Phase III Trial)  
**ç–¾ç—…æ¡ä»¶**: ä¹³è…ºç™Œï¼Œæ”¾å°„æ€§çš®ç‚ (Breast Cancer, Radiation Dermatitis)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE3  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: å±€éƒ¨ä½¿ç”¨å€ä»–ç±³æ¾ (Topical Betamethasone)  
**å¹²é¢„ç±»å‹**: DEVICE  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: Sunnybrook Health Sciences Centre  
**è¯•éªŒåœ°ç‚¹**: Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 276  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2025-03-17  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: N/A  
**ç”µè¯**: N/A  
**é‚®ç®±**: N/A  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06915857)

---

## æ–°è¾…åŠ©SNFç²¾å‡†æ²»ç–—ä¸‰æœŸä¸´åºŠè¯•éªŒ (Neoadjuvant SNF Precision Therapy Phase III)

**è¯•éªŒç¼–å·**: NCT06913777  
**æ­£å¼æ ‡é¢˜**: ä¸€é¡¹å¼€æ”¾æ ‡ç­¾ã€å¤šä¸­å¿ƒã€éšæœºå¯¹ç…§çš„IIIæœŸä¸´åºŠè¯•éªŒï¼Œç ”ç©¶åŸºäºSNFåˆ†ç±»çš„æ—©æœŸæˆ–å±€éƒ¨æ™šæœŸHR+/HER2-ä¹³è…ºç™Œæ–°è¾…åŠ©åŒ–ç–—ï¼Œæ˜¯å¦è”åˆç²¾å‡†åŒ»ç–—è¯ç‰©ã€‚ (An Open-Label, Multicenter, Randomized Controlled Phase III Clinical Study of Neoadjuvant Chemotherapy Based on SNF Classification With or Without Precision Medicine Agents for Early-Stage or Locally Advanced HR+/HER2- Breast Cancer)  
**ç–¾ç—…æ¡ä»¶**: æ–°è¾…åŠ©æ²»ç–—ç–—æ³• (Neoadjuvant Therapy)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE3  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: é’ˆå¯¹æ€§æ²»ç–—è¯ç‰©ï¼šSNF2 -é˜¿å¾·é›·åˆ©å•æŠ—+æ³•ç±³æ›¿å°¼ï¼›SNF3 -æ°Ÿå”‘å¸•åˆ©ï¼›SNF4 -é˜¿å¸•æ›¿å°¼ï¼ŒåŒ–ç–—ï¼ˆwP-ECï¼‰ (Targeted therapy agents: SNF2 -adebrelimab + famitinib; SNF3 -fluzoparib; SNF4 -apatinib, Chemotherapy (wP-EC))  
**å¹²é¢„ç±»å‹**: DRUG, DRUG  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: Fudan University  
**è¯•éªŒåœ°ç‚¹**: Fudan University Shanghai Cancer Center, Shanghai, China  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 404  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2025-03-30  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: N/A  
**ç”µè¯**: N/A  
**é‚®ç®±**: N/A  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06913777)

---

## ä¸€é¡¹è¯„ä¼°Inavolisibè”åˆCDK4/6æŠ‘åˆ¶å‰‚åŠæ¥æ›²å”‘å¯¹æ¯”å®‰æ…°å‰‚+CDK4/6æŠ‘åˆ¶å‰‚å’Œæ¥æ›²å”‘æ²»ç–—å†…åˆ†æ³Œæ•æ„Ÿå‹PIK3CAçªå˜ã€æ¿€ç´ å—ä½“é˜³æ€§ã€HER2é˜´æ€§æ™šæœŸä¹³è…ºç™Œæ‚£è€…çš„ç–—æ•ˆå’Œå®‰å…¨æ€§çš„ç ”ç©¶ã€‚ (A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer)

**è¯•éªŒç¼–å·**: NCT06790693  
**æ­£å¼æ ‡é¢˜**: ä¸€é¡¹ä¸‰æœŸã€å¤šä¸­å¿ƒã€éšæœºã€åŒç›²ã€å®‰æ…°å‰‚å¯¹ç…§ç ”ç©¶ï¼Œè¯„ä¼°Inavolisibè”åˆCDK4/6æŠ‘åˆ¶å‰‚å’Œæ¥æ›²å”‘å¯¹æ¯”å®‰æ…°å‰‚è”åˆCDK4/6æŠ‘åˆ¶å‰‚å’Œæ¥æ›²å”‘ï¼Œåœ¨æ¿€ç´ å—ä½“é˜³æ€§ã€HER2é˜´æ€§ã€å†…åˆ†æ³Œæ•æ„Ÿå‹PIK3CAçªå˜æ™šæœŸä¹³è…ºç™Œæ‚£è€…ä¸­çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ã€‚

<details>
<summary>ğŸ” æŸ¥çœ‹è‹±æ–‡åŸæ–‡</summary>

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

</details>  
**ç–¾ç—…æ¡ä»¶**: ä¹³è…ºç™Œ (Breast Cancer)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE3  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: ä¼Šçº³olisibï¼Œå®‰æ…°å‰‚ï¼ŒCDK4/6æŠ‘åˆ¶å‰‚ï¼Œæ¥æ›²å”‘ (Inavolisib, Placebo, CDK4/6i, Letrozole)  
**å¹²é¢„ç±»å‹**: è¯ç‰©ï¼Œè¯ç‰©ï¼Œè¯ç‰©ï¼Œè¯ç‰©ã€‚ 

ï¼ˆç”±äºæä¾›çš„è‹±æ–‡å†…å®¹ä»…ä¸ºé‡å¤çš„å•è¯"DRUG"ï¼Œç¿»è¯‘ç»“æœäº¦é‡å¤ä»¥ä¿æŒåŸæ–‡å½¢å¼ã€‚ï¼‰ (DRUG, DRUG, DRUG, DRUG)  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: Hoffmann-La Roche  
**è¯•éªŒåœ°ç‚¹**: Northwest Georgia Oncology Centers PC - Marietta, Marietta, United States; Springfield Clinic, Springfield, United States; Nebraska Cancer Specialists, Grand Island, United States  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 450  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2025-01-14  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: N/A  
**ç”µè¯**: N/A  
**é‚®ç®±**: N/A  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06790693)

---

## ç ”ç©¶PF-07220060ä¸æ¥æ›²å”‘è”åˆæ²»ç–—æœªæ¥å—è¿‡æ™šæœŸ/è½¬ç§»æ€§ç–¾ç—…æŠ—ç™Œæ²»ç–—çš„äººHRé˜³æ€§HER2é˜´æ€§ä¹³è…ºç™Œæˆäººæ‚£è€…çš„ç ”ç©¶ã€‚ (Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease)

**è¯•éªŒç¼–å·**: NCT06760637  
**æ­£å¼æ ‡é¢˜**: ä¸€é¡¹å¹²é¢„æ€§ã€å¼€æ”¾æ ‡ç­¾ã€éšæœºã€å¤šä¸­å¿ƒçš„ç¬¬3æœŸç ”ç©¶ï¼Œæ¯”è¾ƒPF-07220060è”åˆæ¥æ›²å”‘ä¸CDK4/6æŠ‘åˆ¶å‰‚è”åˆæ¥æ›²å”‘æ²»ç–—18å²ä»¥ä¸Šã€æ¿€ç´ å—ä½“ï¼ˆHRï¼‰é˜³æ€§ã€HER2é˜´æ€§æ™šæœŸ/è½¬ç§»æ€§ä¹³è…ºç™Œæ‚£è€…ï¼Œä¸”æ­¤å‰æœªæ¥å—è¿‡é’ˆå¯¹æ™šæœŸ/è½¬ç§»æ€§ç–¾ç—…çš„ç³»ç»Ÿæ€§æŠ—ç™Œæ²»ç–—ï¼ˆFOURLIGHT-3ç ”ç©¶ï¼‰ã€‚

<details>
<summary>ğŸ” æŸ¥çœ‹è‹±æ–‡åŸæ–‡</summary>

AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)

</details>  
**ç–¾ç—…æ¡ä»¶**: ä¹³è…ºç™Œ (Breast Cancer)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE3  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: PF-07220060ï¼Œæ¥æ›²å”‘ï¼Œé˜¿è´è¥¿åˆ©ï¼Œå¸•åšè¥¿å°¼ï¼Œç‘åšè¥¿å°¼ã€‚ (PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib)  
**å¹²é¢„ç±»å‹**: è¯ç‰©ï¼Œè¯ç‰©ï¼Œè¯ç‰©ï¼Œè¯ç‰©ï¼Œè¯ç‰©ã€‚ (DRUG, DRUG, DRUG, DRUG, DRUG)  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: Pfizer  
**è¯•éªŒåœ°ç‚¹**: Ironwood Cancer & Research Centers, Chandler, United States; Ironwood Cancer & Research Centers, Gilbert, United States; Ironwood Cancer & Research Centers, Glendale, United States  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 1020  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2024-12-11  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: N/A  
**ç”µè¯**: N/A  
**é‚®ç®±**: N/A  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06760637)

---

## JSKN003 ä¸æ›²å¦¥ç å•æŠ—åŸƒå¦å¡ (T-DM1) ç”¨äºHER2é˜³æ€§æ™šæœŸä¹³è…ºç™Œçš„æ¯”è¾ƒç ”ç©¶ã€‚ (JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer)

**è¯•éªŒç¼–å·**: NCT06846437  
**æ­£å¼æ ‡é¢˜**: ä¸€é¡¹éšæœºã€å¯¹ç…§ã€å¼€æ”¾æ ‡ç­¾ã€å¤šä¸­å¿ƒã€â…¢æœŸä¸´åºŠè¯•éªŒï¼Œæ¯”è¾ƒJSKN003ä¸æ©å¦è¾›æ›²å¦¥ç å•æŠ—ï¼ˆT-DM1ï¼‰åœ¨HER2é˜³æ€§æ™šæœŸä¹³è…ºç™Œæ‚£è€…ä¸­çš„ç–—æ•ˆä¸å®‰å…¨æ€§ã€‚ (A Randomized, Controlled, Open-Label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer Subjects)  
**ç–¾ç—…æ¡ä»¶**: ä¸å¯æ‰‹æœ¯çš„å±€éƒ¨æ™šæœŸæˆ–HER2é˜³æ€§ä¹³è…ºç™Œè½¬ç§»æ‚£è€…å‚ä¸è€… (Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE3  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: JSKN003ï¼Œæ›²å¦¥ç å•æŠ—-emtansineï¼ˆT-DM1ï¼‰ (JSKN003, Trastuzumab emtansine (T-DM1))  
**å¹²é¢„ç±»å‹**: DRUG, DRUG  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: Shanghai JMT-Bio Inc.  
**è¯•éªŒåœ°ç‚¹**: Fudan University Shanghai Cancer Center, Shanghai, China  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 228  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2025-01-06  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: N/A  
**ç”µè¯**: N/A  
**é‚®ç®±**: N/A  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06846437)

---

## æ¯”è¾ƒç«–è„Šè‚Œå¹³é¢é˜»æ»ä¸è‚‹é—´å‰è‚Œå¹³é¢é˜»æ»åœ¨æ”¹è‰¯æ ¹æ²»æ€§ä¹³æˆ¿åˆ‡é™¤æœ¯åé•‡ç—›æ•ˆæœæ–¹é¢çš„å·®å¼‚ã€‚ (Comparison Between Erector Spinae Plane Block Versus Serratus Anterior Plane Block Regarding Analgesia Post Modified Radical Mastectomy)

**è¯•éªŒç¼–å·**: NCT06947330  
**æ­£å¼æ ‡é¢˜**: æ¯”è¾ƒè¶…å£°å¼•å¯¼ä¸‹ç«–è„Šè‚Œå¹³é¢é˜»æ»ä¸è¶…å£°å¼•å¯¼ä¸‹å‰é”¯è‚Œå¹³é¢é˜»æ»åœ¨æ”¹è‰¯æ ¹æ²»æ€§ä¹³è…ºåˆ‡é™¤æœ¯åé•‡ç—›æ•ˆæœæ–¹é¢çš„å·®å¼‚ã€‚ (Comparison Between Ultrasound Guided Erector Spinae Plane Block Versus Ultrasound Guided Serratus Anterior Plane Block Regarding Analgesia Post Modified Radical Mastectomy)  
**ç–¾ç—…æ¡ä»¶**: æ”¹è‰¯æ ¹æ²»æ€§ä¹³è…ºåˆ‡é™¤æœ¯ï¼Œä¹³è…ºç™Œ (Modified Radical Mastectomy, Breast Cancer)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE3  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: å•ä¾§ç«–è„Šè‚Œç¾¤ï¼Œå•ä¾§å‰é”¯è‚Œç¾¤ (Unilateral Erector Spinae group, Unilateral Serratus Anterior group)  
**å¹²é¢„ç±»å‹**: ç¨‹åºï¼Œç¨‹åº

ï¼ˆç”±äºæ‚¨æœªæä¾›å…·ä½“çš„è‹±æ–‡å†…å®¹ï¼Œæˆ‘æ— æ³•è¿›è¡Œå…·ä½“ç¿»è¯‘ã€‚å¦‚æœæä¾›å…·ä½“æ–‡æœ¬ï¼Œæˆ‘å°†èƒ½å¤Ÿå‡†ç¡®ç¿»è¯‘ã€‚ï¼‰ (PROCEDURE, PROCEDURE)  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: Kholoud Usama  
**è¯•éªŒåœ°ç‚¹**: Faculty of Medicine, Ain-Shams University, Cairo, Egypt  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 100  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2025-04-13  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: N/A  
**ç”µè¯**: N/A  
**é‚®ç®±**: N/A  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06947330)

---

